Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2020 | PD-1 and OX40: potential PDAC combination therapy

Cassian Yee • 28 Sep 2020
ITOC 2020
Pancreatic Cancer Antibodies

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the combination of PD-1 inhibitor with OX40 agonist which induced tumor rejection and immune memory in mice with pancreatic tumors. This information can be used in the development of future immune-based combination therapies for pancreatic ductal adenocarcinoma (PDAC). This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

More from Cassian Yee

5:07
HDACi and IL21: reprogramming CD8+ T-cells to memory T-cells
Cassian Yee • 28 Sep 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:16
Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti • 9 Apr 2024
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
0:48
Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma
Olatunji Alese • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals